⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.
LALPATHLAB - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 3.3
| Stock Code | LALPATHLAB | Market Cap | 23,821 Cr. | Current Price | 1,422 ₹ | High / Low | 1,771 ₹ |
| Stock P/E | 44.4 | Book Value | 140 ₹ | Dividend Yield | 0.85 % | ROCE | 30.6 % |
| ROE | 24.7 % | Face Value | 10.0 ₹ | DMA 50 | 1,452 ₹ | DMA 200 | 1,488 ₹ |
| Chg in FII Hold | -1.57 % | Chg in DII Hold | 0.98 % | PAT Qtr | 113 Cr. | PAT Prev Qtr | 146 Cr. |
| RSI | 51.1 | MACD | -14.2 | Volume | 1,39,146 | Avg Vol 1Wk | 2,46,829 |
| Low price | 1,147 ₹ | High price | 1,771 ₹ | PEG Ratio | 3.36 | Debt to equity | 0.06 |
| 52w Index | 44.0 % | Qtr Profit Var | 7.24 % | EPS | 30.8 ₹ | Industry PE | 36.0 |
📊 Technical Analysis
- Chart Patterns: Stock has corrected from 1,771 ₹ high to 1,422 ₹, showing weakness but holding above 52-week low (1,147 ₹).
- Moving Averages: Current price is slightly below 50 DMA (1,452 ₹) and 200 DMA (1,488 ₹), indicating mild bearish bias.
- RSI: 51.1 — neutral zone, neither overbought nor oversold.
- MACD: -14.2 — bearish crossover, momentum weak.
- Bollinger Bands: Price near mid-band, suggesting consolidation.
- Volume Trends: Current volume (1.39L) is below 1-week average (2.46L), showing reduced participation.
📈 Momentum & Signals
- Short-term Momentum: Neutral to weak, with consolidation signals.
- Support Levels: Strong support near 1,380–1,400 ₹.
- Resistance Levels: Immediate resistance at 1,452 ₹ (50 DMA), next at 1,488 ₹ (200 DMA).
- Optimal Entry Zone: 1,380–1,420 ₹ (near support).
- Optimal Exit Zone: 1,460–1,500 ₹ (near DMA resistances).
- Trend Status: Stock is consolidating with mild bearish undertone.
✅ Positive
- Strong ROCE (30.6%) and ROE (24.7%) indicate efficient capital use.
- Low debt-to-equity (0.06) ensures financial stability.
- Dividend yield of 0.85% adds investor appeal.
⚠️ Limitation
- Stock P/E (44.4) is higher than industry P/E (36.0), suggesting relative overvaluation.
- PEG ratio of 3.36 indicates expensive valuation compared to growth.
- Price trading below both 50 DMA and 200 DMA shows weak momentum.
📉 Company Negative News
- Quarterly PAT declined (113 Cr vs 146 Cr).
- FII holding decreased by -1.57%, showing reduced foreign investor confidence.
📈 Company Positive News
- DII holding increased by 0.98%, showing domestic institutional support.
- Quarterly profit variation (+7.24%) indicates operational resilience despite decline.
🏭 Industry
- Industry P/E at 36.0 is lower than LALPATHLAB, highlighting relative overvaluation.
- Diagnostics sector remains growth-oriented, supported by rising healthcare demand.
📝 Conclusion
- LALPATHLAB is in a consolidation phase with mild bearish undertone.
- Best strategy: Accumulate near support (1,380–1,420 ₹) and book profits near resistance (1,460–1,500 ₹).
- Long-term investors may hold given strong fundamentals, but valuation remains stretched compared to industry peers.